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 KORELASI ANTARA PARAS INTERLEUKIN 31 DI DALAM DARAH 
PESAKIT ATOPIC DERMATITIS, ALLERGIC RHINITIS                               
DAN ATOPIC ASTHMA 
 
ABSTRAK 
 
 Interleukin 31 (IL-31), merupakan salah satu daripada sitokin yang menjadi 
pengawal atur yang penting terhadap tindak balas TH2. Kajian terdahulu telah dilakukan 
oleh Zhang et al. (2008), untuk mengukur paras IL-31 di kalangan atopic dermatitis 
(AD). Walaubagaimanapun, paras IL-31 di kalangan allergic rhinitis (AR) dan atopic 
asthma (AA) adalah masih tidak jelas. Objektif-objektif dalam kajian “cross sectional” 
ini adalah untuk mengukur paras IL-31 di kalangan AD, AR dan AA, untuk mengukur 
korelasi antara IL-31 dan faktor-faktor yang mempengaruhi penyakit, untuk mengukur 
IL-31 dan tahap keterukan penyakit dan untuk mengukur paras IL-31 dan pruritus di 
kalangan pesakit. Kajian ini melibatkan 70 pesakit AD dari Klinik Kulit, Hospital 
Universiti Sains Malaysia (HUSM) dan Hospital Raja Perempuan Zainab II (HRPZ II), 
70 pesakit AR dari Klinik Telinga, Hidung dan Tekak (ENT) di HUSM, 70 pesakit AA 
dari Klinik Dada dan Klinik Kanak-kanak di HUSM dan 70 subjek sihat (staf dan 
individu di HUSM). Lima mililiter darah diambil dan diemparkan untuk 5 minit pada 
2000 putaran perminit (rpm) untuk mendapatkan serum dan dianalisa untuk paras IL-31 
menggunakan kit “enzyme-linked immunosorbent” (ELISA) (Human IL-31 Duoset, 
R&D System). “Independent t-test” adalah kaedah statistic yang digunakan untuk 
melihat perbezaan paras IL-31 antara individu sihat dan penyakit alergik begitu juga 
xviii 
paras IL-31 dan pruritus di kalangan pesakit. “Simple” dan “multiple logistic 
regressions” digunakan untuk menganalisa korelasi. “Kruskal Wallis test” digunakan 
untuk mengukur paras IL-31 dan tahap keterukan AD dan AA dan “Mann-Whitney test” 
digunakan untuk mengukur paras IL-31 dan tahap keterukan AR. Hasil kajian 
menunjukkan bahawa tiada perbezaan yang jelas dalam min (sisihan piawai) di antara 
paras IL-31 dalam kalangan penyakit, 5048.79 (24628.27) and individu sihat, 2195.55 
(9016.57) (p=0.344). Paras IL-31 dan faktor-faktor yang mempengaruhi menunjukkan 
hubungan yang jelas di dalam status merokok, pendedahan pekerjaan dan kawasan 
tempat tinggal bagi AD dan AR, walaubagaimanapun dalam AA, hubungan yang jelas 
hanya didapati di dalam status merokok dan pendedahan pekerjaan. Kajian 
menunjukkan tiada perbezaan yang jelas di antara paras IL-31 dan tahap keterukan 
penyakit alergik, AD (p=0.104), AR (p=0.245) dan AA (p=0.745). Keputusan 
menunjukkan tiada perbezaan yang jelas di antara paras IL-31 dan pruritus di dalam 
pesakit dengan min (sisihan piawai) di dalam “pruritic”, 6168.25 (30552.07) and “non-
pruritic”, 3693.64 (14600.99).      
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 CORRELATION OF INTERLEUKIN 31 SERUM LEVELS IN PATIENTS 
WITH ATOPIC DERMATITIS, ALLERGIC RHINITIS AND ATOPIC 
ASTHMA 
 
ABSTRACT 
 
 Interleukin 31 (IL-31), is one of the cytokines which appears to be an important 
regulator of TH2 responses. Previous study has been done by Zhang et al. (2008), to 
determine IL-31 serums levels in atopic dermatitis (AD). However, the serum levels of 
IL-31 in allergic rhinitis (AR) and atopic asthma (AA) is still unclear. The objectives of 
this cross sectional study are to determine IL-31 serum levels in AD, AR and AA, to 
study the association between IL-31 and predisposing factors with allergic diseases, to 
correlate IL-31 levels and the severity of allergic diseases and to compare IL-31 levels 
and pruritus in patients with allergic diseases. This study involved 70 patients with AD 
from the skin clinic of Hospital Universiti Sains Malaysia (HUSM) and Hospital Raja 
Perempuan Zainab II (HRPZ II), 70 patients with AR from the Ear, Nose and Throat 
Clinic (ENT clinic) of HUSM, 70 patients with AA from the Chest Clinic and Pediatrics 
Clinic of HUSM and 70 healthy controls (staff and people of HUSM). Five milliliters of 
blood were withdrawn and centrifuged for 5 minutes at 2000 rpm to obtain the serum 
and analyzed for IL-31 levels by using enzyme-linked immunosorbent (ELISA) kits 
(Human IL-31 Duoset, R&D System). Independent t-test was the statistical method used 
to compare IL-31 levels between healthy controls and allergic diseases as well as IL-31 
levels and pruritus in allergy. Simple and multiple logistic regressions were used to 
xx 
analyze the association. Kruskal Wallis test was used to determine IL-31 levels and the 
severity of AD and AA and Mann-Whitney test was used to determine IL-31 and the 
severity of AR. The results showed that there was no statistically significant difference 
of mean (SD) of IL-31 levels among diseases, 5048.79 (24628.27) and controls, 2195.55 
(9016.57) (p=0.344). The levels of IL-31 and other predisposing factors showed 
significant associations in smoking status, occupational exposure and area of living for 
AD and AR, however in AA, the significant association only found in smoking status 
and occupational exposure. There was no significant difference between IL-31 levels 
and the severity of allergic diseases, AD (p=0.104), AR (p=0.245) and AA (p=0.745). 
The results showed there was no significant differences between IL-31 levels and 
pruritus in patients with mean (SD) in pruritic, 6168.25 (30552.07) and non-pruritic, 
3693.64 (14600.99).     
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
 
 
1.1  Allergy and atopy 
 In 1906, Clemens P.Pirquet introduced the term of “allergy” to describe the 
reaction of protective immunity and hypersensitivity (Bukantz, 2002). Later, allergy was 
used to describe the unexpectable reactions in the skin and mucosa (Wuthrich, 1999). 
Allergy usually refers to the clinical expression of atopic IgE-mediated disease. It is 
often expressed towards a target organ (Durham and Church, 2001).  
Atopy refers to the implication to an allergic disease due to IgE response to one or 
several common environmental allergens (Gusareva et al., 2009). Clinical symptoms 
may or may not found in atopic individuals. Individuals that suffer atopy produce 
abnormally high levels of IgE in response to the allergens and overexpression of IgE 
receptors than normal people (Corrigan and Kay, 1992; Abbas et al., 1994).   
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1.2 Atopic dermatitis 
 Atopic dermatitis (AD) is a chronic inflammation manifested by itchiness of the 
skin. Patients with AD demonstrate a range of primary pruritic lesions including 
macular erythema, a fine papular eruption, erythematous urticaria, indurated papules, 
plaque and diffuse edematous erythema. The scurf is characterized by itchy papules that 
become excoriated and lichenified (Friedman and Holden, 2004). A study done in 
Granada, Spain stated that 60.7% of the population were never awaken at night because 
of the AD, 11.8% said that they had woken less than once per week and 2.2% showed 
they were awaken once or more per week (Guiote-Dominguez et al., 2008). 
 
1.2.1 Prevalence study of atopic dermatitis 
 Females are more affected to this allergic diseases compared to males as reported 
by Kapoor et al. (2008). A recent study reported that 80.0% of the patients suffered AD 
in their family. About 1/3 of AD patients also suffered from asthma and allergic rhinitis. 
Patients with AD are prone to get AR and AA (Asher et al., 2006).  
The worldwide prevalence showed an increasing trend of allergic diseases (Cookson et 
al., 2001; Nomura et al., 2003; Cookson et al., 2004; Marenholz et al., 2006; Morar et 
al., 2006). The annual prevalence of AD appears to be increased. 
A study in Granada found that 29.4% of their schoolchildren had been diagnosed with 
AD. The prevalence of AD among 6 to 7 years old (36.1%) was higher between 13 and 
2 
14 (23.5%). The diagnosis of AD was higher among those living in the urban areas than 
those living along the coastal region (Guiote-Dominguez et al., 2008).  
The previous studies in Nikel, Russia done by Dotterud et al. (2004), and Ulsan, Korea 
done by Kim et al. (2000), reported that lower prevalences were found in industrialized 
areas than in nonindustrialized part. However, the studies done in Jimma, (Ethiopia) by 
Yemaneberhan et al. (2004) and Seoul (Korea) done by Kim et al. (2000) showed the 
higher prevalence of AD was found in urban areas than in rural ones.         
A previous study done in Malaysia, found that the overall prevalence of AD symptoms 
was 12.0%. The prevalence of AD in the 5 to 7 year age group was recorded 13.7% 
while among 12 to 14 year age group showed 9.9% (Quah et al., 1997). 
The results showed no significant changes in the prevalence of symptoms in the 
previous 12 months (1995 vs 2001) in the same study. These were also no major 
changes in the prevalence rates of these diseases over a period of 6 years (Quah et al., 
2005). 
   
1.2.2 Aetiology of atopic dermatitis  
 There are various factors that contribute to the expression of AD. They can be 
environmental, genetic and immunological factors (Gustafsson et al., 2000; Abramovits 
and Abramovits, 2005; Asher et al., 2006; Fiset et al., 2006). The triggers of atopic 
dermatitis also included foods, house dust mites, emotional factors as well as skin 
irritants. 
3 
Hygiene hypothesis can be the best explanation for the development of AD (Holt, 2000). 
This reason was explained with the exposure to pollutants. However, in some way it 
protects against the development of atopy. The exposure to infectious diseases which 
were associated with poorer, less developed nations also protects against atopy. 
 
1.2.3 Clinical manifestations of atopic dermatitis 
 The major symptoms of AD include pruritus, dermatitis affecting flexural 
surfaces in adults, face and extensors in infants. There is usually also history of chronic 
or relapsing dermatitis and personal or family history of cutaneous or respiratory atopy. 
The minor symptoms consist of features of so-called atopic facies : facial pallor or 
erythema, hypopigmented patches, infraorbital darkening, infraorbital folds or wrinkles, 
cheilitis (inflammation of the lip), recurrent conjunctivitis and anterior neck folds. 
The other symptoms of AD also include dry skin, ichthyosis (excessive amounts of dry 
surface scales), hyperlinear palms, keratosis pilaris (plugged hair follicles of the 
proximal extremities), hand and foot dermatitis, nipple eczema, white dermatographism 
and perifollicular accentuation. AD patients may also have emotional disturbances such 
as feeling anxious and unable to manage anger in certain circumstances (Ginsburg et al., 
1993). 
The intensely pruritic, erythematous macules or papules can present initially in acute 
lesions of AD. With the scratching of the primary lesions, secondary lesions may occur 
as excoriated papules with serum exudates and crust. In young children, lesions tend to 
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appear on the scalp, face and extensor surface of the legs and arms. In older children, 
lesion occurs within the flexural areas of the extremities.  
In both children and adult, skin of AD is dry and this reflects loss of cutaneous barrier 
function (Blauvelt et al., 2003). AD skin has increased permeability to microbes as well 
as other allergens. Chronic AD appeared to have lichenification (thickening) of the skin. 
With intense scratching or rubbing, the epidermis may result to prurigo nodules.  
 
1.2.4 Scoring system of atopic dermatitis (Objective SCORAD) 
 Objective SCORAD was used to determine the severity of AD. In the Objective 
SCORAD, mild eczema is defined as a score less than 15, for moderate eczema a score 
is more than 15 but less than 40 and for severe AD, the score is greater than 40.  
The severity of AD is classified by using Objective SCORAD which include the 
extension of the disease (A) and the intensity of the disease (B) with mean calculation (1 
for mild, 2 for moderate and 3 for severe). The distribution of the score is achieved 
using the formula A⁄5 + 7B⁄2. 
The interpretation of disorder are (A: according to the rule of nines; 20% of the score), 
the intensity composed of six items (B: erythema, oedema ⁄papules, effect of scratching, 
oozing ⁄crust formation, lichenification and dryness; 60% of the score; each item has 
four grades: 0, 1, 2, 3). The maximum score can reach 93.  
In this study, Objective SCORAD system is used based on a European consensus. This 
system is representative and well evaluated but shows, as with other systems, intra- and 
5 
interobserver disagreements. The Objective SCORAD gives more information about 
extent and intensity of eczema. Therefore the Objective SCORAD should be used in 
clinical comparative trials. 
 
1.2.5 Pathophysiology of atopic dermatitis 
 AD resulted from dysregulated Th2-biased immune responses to the 
environmental stimuli (Leung and Soter, 2001). An increasing number of eosinophils is 
found in the blood with a corresponding elevated IgE levels in AD. Allergen-specific T 
cells that produce cytokines also appear to be increased in the peripheral blood of AD 
patients. In addition to promote the antibody responses, the cytokines also inhibit the 
ability of the T cells to generate TH1 cytokines. 
Blood mononuclear cells from AD patients have reduced capacity to generate this 
critical TH1 cytokine. The loss of IFN-γ (interferon gamma) may be a critical 
pathophysiologic mechanism in atopic disease as AD patients respond well to treatment 
with IFN-γ (Stevens et al., 1998).  
TH1 supportive cytokine that up-regulate IFN-γ, is also down-regulated in AD subjects 
(Ong et al., 2002). Previous evidence showed that chemokines and their proteins could 
play an important role in the recruitment of specific immune populations into the skin in 
AD and other inflammatory skin conditions (Locati and Murphy, 1999).  
The shift in balance between cytokines produced by TH1 and TH2 towards TH2 
predominance might trigger allergic inflammation (Scavuzzo et al., 2003; Ciprandi et 
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al., 2009). TH2 lymphocyte proliferation is induced by the allergen with the release of 
characteristic combination of cytokines and granulocyte-macrophage colony stimulating 
factor (GM-CSF) (Scavuzzo et al., 2003). Cytokines like IL-18 appear to be an essential 
requirement for IgE production.  
Filaggrin (FLG) is a filament-associated protein that binds to keratin fibers in epithelial 
cells. It plays an important role in skin barrier. AD tends to develop in individuals that 
carrying the FLG null allele variants (Palmer et al., 2006). FLG protein is located in the 
granular layers of the epidermis. FLG monomers are degraded into natural moisturizing 
factors by bleomycin hydrolase or caspase 14 which are important hydration 
maintenance and ensuring skin pH low. The FLG gene within intragenic copy number 
variation (20-24 copies in one person) can contribute to AD with a dose dependent 
effect (Brown et al., 2012).  
Treg (regulatory T) cell, exists in the skin which is one of the non-lymphoid tissues. It 
composes of a high proportion of Treg. Treg in the skin are CD44 and CD103 (Sather et 
al., 2007; Dudda et al., 2008; Tomura et al., 2010). Chemokine receptors which 
included of CCR4, CCR5, CCR6 and CCR7 are expressed by Treg. A complete loss of 
CCR4 on Treg might contribute to spontaneous lymphocytic infiltration and severe 
inflammation in the skin and lungs. The development of AD lesion is related to Treg 
(Ochs et al., 2005). The number of Treg in the blood can be altered by using the 
treatment for AD such as cyclosporine and glucocorticoid (Brandt et al., 2009; Hijnen et 
al., 2009; Loser & Beissert, 2009; Baumgrass et al., 2010; Stary et al., 2011). 
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Polymorphism is resulted in elevated expression at the protein level. Overexpression of 
IL-1 by microglial cells correlates with the formation of neuritic beta-amyloid plaques in 
AD (Mrak et al., 1995). The genotypes that overexpress IL-1 confer risk for AD through 
this mechanism. An additional polymorphism in the C allele of a variable number of 
tandem repeats (VNTR) in the 3 region of the IL-6 gene is also associated with AD. It 
has been shown to confer delayed onset and reduced risk of disease.  
Polymorphism may be in linkage disequilibrium with yet another polymorphism leading 
to reduced expression of IL-6 (Papassotiroppoulos et al, 1999). Lack of IL-6 may 
protect neural tissue directly. Alternatively it may do so by ameliorating an 
inflammatory reaction involved in the pathogenesis of AD. 
This latter concept is supported by the finding that individuals exposed to anti-
inflammatory agents such as non-steroidal anti-inflammatory drugs have a lower 
probability of developing AD (Breitner et al., 1994).  
 
1.2.6 Diagnosis of atopic dermatitis 
 The diagnosis of AD is basically from the clinical history and physical 
examination. The diagnosis of AD is based on the clinical features such as pruritus, a 
chronic relapsing course and also family history of the triad diseases (AD, AR and AA). 
The diagnosis of AD requires the presence of at least three major symptoms and at least 
three minor symptoms. Exposure to possible exacerbating factors, such as aeroallergens, 
irritating chemicals, foods and emotional stress, should be investigated. 
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Unfortunately, there is no specific laboratory finding or histologic features to define AD. 
Although elevated IgE levels are found in up to 80.0% of affected patients, IgE levels 
are also elevated in patients with other atopic diseases (Leung, 1995).  
IgE levels can be checked by using serum IgE immunoassay with ImmunoCAP 
machine. The technology is based on an extremely high total binding capacity, achieved 
through a high binding capacity per mg cellulose in combination with an optimal 
amount of cellulose in each solid phase. The allergen of interest, covalently coupled to 
the solid phase, reacts with the specific IgE in the patient sample. After washing away 
non-specific IgE, enzyme-labelled antibodies against IgE are added to form a complex. 
After incubation, unbound enzyme-labelled anti-IgE is washed away and the bound 
complex is then incubated with a developing agent. After stopping the reaction, the 
fluorescence of the eluate is measured. The higher the fluorescence, the more specific 
IgE is present in the sample (Thermo Fisher Scientific, 2011).  
Instead of ImmunoCAP, the latest test used to determine specific IgE is allergodip. This 
is an enzyme immunoassay (EIA) for the semiquantitative determination of specific IgE 
in serum or plasma. It does not require any laboratory equipment as it comes with ready 
to use reagents. Specific IgE from the sample binds with the allergen with allergen 
coupled to the solid phase. The unbound material is removed in a washing phase. 
Enzyme labelled anti-IgE is added which binds to any specific IgE. The unbound anti-
IgE is removed in washing phase. Substrate is added and the solution is incubated. The 
intensity of the blue colour is compared with colour chart. The amount of specific IgE is 
estimated using class scoring system (Thermo Fisher Scientific, 2011).  
9 
In skin testing, the positive and negative controls must be used to ensure the validity of 
the results. Skin testing can be affected by patient age, quality of extract, sensitivity 
towards allergens which included antihistamines and antidepressants, volume and 
antigen’s patent, reactivity of the skin, race, area of body tested and distance between 
injections (Rosenwasser, 2002) 
Serum IgE immunoassay is less traumatic compared to skin prick test. However, it is 
less sensitive and the results are not released promptly (Nguyen and Close, 2005). The 
results can be obtained within two days.  
    
1.2.7 Treatment of atopic dermatitis 
 The successful treatment of AD requires relief of pruritus, having barrier 
function of the skin and elimination of environmental characteristics that contribute to 
AD disease and repairment of inflammation (Tofte and Hanifin, 2001). For severe 
pruritus, doxepin hydrochloride blocks both H1 and H2 histamine receptors. The 
relationship between dry skin and AD can be avoided by avoiding hot shower, occlusive 
dressings on traumatized skin and other avoidance techniques. Topical corticosteroid is 
still the treatment for AD. For moderate to severe AD, ointment-based corticosteroids 
and higher potential agents should be used to control the disease promptly.  
Tacrolimus and pimecrolimus bind to the binding protein and block T-cell function 
through inhibition of calcineurin-dependent transcription of genes (Paller et al., 2001). 
In severe AD, ultraviolet light therapy and other devices have immunosuppressive 
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effects secondary to its ability to induce apoptosis and able to stimulate keratinocyte 
production of cytokines (Reynolds et al., 2001).  
TH1 cytokine had shown to be safe and long term daily treatment of AD patients is able 
to reduce other atopic symptoms (Stevens et al., 1998). AD-specific chemokines that 
attract TH2 cells and eosinophils can be explored in order to treat this disease as far as 
therapeutics target is concerned. 
 
1.3 Allergic rhinitis  
 Allergic rhinitis (AR) is defined as an IgE-mediated inflammation of nasal 
mucosa, characterized by one or multiple of the major symptoms like nasal obstruction, 
rhinorrea, sneezing and nose itchness (International Rhinitis Management Working 
Group, 1994). AR has been recognized in recent years as a disease requiring attention. 
Classically, simple rating diagnostic of severity were recorded which included of mild 
AR and moderate to severe AR (Juniper et al., 2005). 
 
1.3.1 Prevalence study of allergic rhinitis 
 Ten to twenty five percent (10.0% to 25.0%) of the population in the world were 
affected with allergic rhinitis (AR) (Lynch, 2004; Noriaki et al., 2006). The most 
common of all atopic diseases is AR which has been estimated to affect up to 40.0% of 
the children in the United States (Rosenwasser, 2002) and 20.0% of the adult population 
in the world (Corren, 2000).  
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Most of the patients report the onset of the symptoms before 30 years of the age or 
during some of the most productive years of life although AR can develop at any age 
(Corren, 2000). The sex proportion is equal for males and females (Parslow et al., 
2001).  
Over the past 40 years, there is a substantial increased in the prevalence of AR 
worldwide (Noriaki et al., 2006) with a higher increase reported in an industrialization 
part and in developing countries as well as rural populations (Rosenwasser, 2002). The 
prevalence of allergic diseases had increased predominantly in urban areas and 
developing countries. 
Seasonal AR is found in approximately 10.0% to 20.0% in the perennial rhinitis of the 
population and 10.0% of the general population (Meltzer, 1997). From 1971 to 1981, an 
increased prevalence was shown in a Swiss population. The prevalence of AR since this 
time increased from 4.4% to 8.4% (Spector, 1997).  
The previous study showed that the families with a bilateral family history of allergy 
generally tend to have children having symptoms of allergy before puberty. Those with 
a unilateral family history tend to have symptoms later in life or not at all. In 1 of 5 
children by 2 to 3 years of age, the children tend to have development symptoms of AR 
and approximately 40.0% by age of 6. During adolescence, the development of 
symptoms will turn in approximately 30.0%. 
The study done in Singapore estimated general population prevalence of chronic rhinitis 
was 10.8%. Higher prevalences were recorded in males, in younger adults, in Indians 
and Chinese and those with higher socio-economic status. AR was highly significantly 
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associated with asthma as reported in the previous study (Ng and Tan, 1994). The study 
done in Kelantan, Malaysia stated that there is no significant difference between gender 
and AR in the prevalence observed (Quah et al., 1997). 
 
1.3.2 Aetiology of allergic rhinitis 
 Lifestyle and environmental risk factors (The International Study of Asthma and 
Allergies in Childhood (ISAAC) Steering Committee, 1998; Sly, 1999) as well as 
heredity (Porsbjerg et al., 2002) seem to be major determinants of allergic diseases. 
There are many factors triggering this disease such as family history of allergic, parental 
smoking background, sex and early exposure to allergens or pollutions (Tamay et al., 
2007). The other factors such as age, gender and place of resident also associated with 
allergic sensitization.  
The other risk as well as predisposing factors include elevated serum IgE levels (>100 
IU/ml) before 6 years of age, introduction to food formula early in infancy, exposure to 
indoor allergens, primary or secondary heavy exposure to cigarette smoke and higher 
socioeconomic status (Rosenwasser, 2002). The increasing trend of allergic diseases 
prevalence has been partly explained by “hygiene hypothesis”, suggesting that reducing 
microbial exposure in early childhood skewing the reciprocal balance from TH1 to TH2 
towards TH2-mediated allergic disorders (Tamay et al., 2007).  
In Malaysia, the most common allergens that trigger the symptoms of AR are house dust 
mites Dermatophagoides pteronyssinus and Dermatophagoides farina (Wan Majdiah et 
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al., 2011). The other allergens that precipitate the symptoms of AR include cat fur, milk, 
shrimp and weed (Choon-Kook and Teck-Soong, 1995). Cat fur was found the 
commonest animal allergen among Kelantanese (Elango et al., 1989). The most 
common allergens found in US are animal allergens, grass pollen, trees, weeds, fungi 
and dust mites (Naclerio and Solomon, 1997).   
  
1.3.3 Clinical manifestations of allergic rhinitis 
 The symptoms of AR includes nasal itchiness, rhinorrhoea, nasal obstruction, 
sneezing, ear fullness, nasal congestion, post nasal drip, itchy, puffy red and watery eyes 
(Rutkowski, 2005; Lehman and Lieberman, 2007; Masuda and Schmitz, 2007). This is 
also normally associated with ocular symptoms (Rondon et al., 2007; Rondon et al., 
2008; Rondon et al., 2009).  
The symptoms which involving the ears, eyes and throat including postnasal drainage 
were frequently accompanied (Parslow et al., 2001; Skoner, 2001). Postnasal drainage 
can lead to sore throat, clearing of the throat and cough. Severe attacks of AR are 
usually followed by systemic malaise, fatigue and weakness. The headache is due to 
obstruction of the ostium of the paranasal sinuses occurred as a result of swelling of the 
nasal mucosa overlying it (Parslow et al., 2001). 
AR has significant effect on the quality of life of patients such as sleep, daily activities, 
work and school performance (ARIA, 2001; Rutkowski, 2005; Valero et al., 2007). 
Even though it is not life threatening, it is now causing substantial medical care 
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expenditure as well as impairment both physical and cognitive functions in adult 
(Corren, 2000). AR is also associated with the patient’s complaint, like impairments 
function at home, work and school. Patients might be interrupted by sleep disorders, 
impairment in activities, emotional problems and social functioning (ARIA, 2001; 
Bousquet et al., 2006).  
In chronic or severe AR, a transverse nasal salute is often seen across the bridge of the 
nose. The palpebral conjunctivae may be injected with a watery discharge and puffiness 
of the eyelids (Lehman and Lieberman, 2007). There are systemic manifestations of the 
allergic inflammation at these sites (Bousquet et al., 2008).  
 
1.3.4 Scoring system of allergic rhinitis (ARIA classification)  
 
 In the ARIA classification, allergic rhinitis can be classified as mild or moderate 
to severe depending on the severity of the symptoms and their impact on social life, 
school and work. It has also been proposed to classify the severity as mild, moderate or 
severe (Van Hoecke et al., 2006a; 2006b; Valero et al., 2007). Traditionally, AR has 
been classified as seasonal or perennial. It was depending on the symptoms occurred. 
Currently, a new classification for AR based on the duration and severity of symptoms 
had been proposed (ARIA, 2001; Lehman and Lieberman, 2007).  
Mild AR is defined according to symptoms such as normal sleep, no impairment of 
daily activities, sport or leisure, normal work and school and no troublesome symptoms. 
Moderate to severe AR is defined when more items occurring such as abnormal sleep, 
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impairment of daily activities, sport or leisure, impairment of work or school and 
troublesome symptoms.  
Based on duration, AR is divided into persistent and intermittent disease and for 
severity, it is divided into mild or moderate to severe (Table 1.1). The intensity was 
depending on symptoms and quality of life parameters (ARIA, 2001; Lynch, 2004). 
Majority of patients with AR reported to have persistent rhinitis with moderate-to-severe 
symptoms (Rondon et al., 2011) frequently associated with conjunctivitis (25% to 57%) 
and asthma (33% to 47%) (Rondon et al., 2007; Rondon et al., 2008).  
 
Table 1.1 : Classification of allergic rhinitis by using ARIA classification  
 
          Intermittent                     Persistent 
 
Duration  Symptoms occur on less than                 Symptoms occur on the majority 
   4 days a week, or less than 28      of days of the week and for more 
   days at a time         than 28 days 
 
 
        Mild AR             Moderate to severe AR 
 
Severity    No disturbance in sleep, leisure,          Disturbance to sleep, leisure 
     school or work activities           school or work activities 
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1.3.5 Pathophysiology of allergic rhinitis  
 A characterization of pathophysiologic mechanisms (endotypes) and clinical 
manifestations (phenotypes) is needed for a better understanding of AR. Several authors 
had studied a concept of local production of IgE in nasal mucosa of patients with AR. 
The previous study has found the expression of ε germline gene transcripts and mRNA 
for the ε heavy chain of IgE in nasal B cells (Durham et al., 1997; Coker et al., 2003).  
Further research has demonstrated the existence of class-switch recombination to IgE in 
nasal mucosa of patients with AR (Durham et al., 1997; Coker et al., 2003). More 
evidence supporting the local synthesis of sIgE (specific immunoglobulin E) in the nasal 
mucosa of patients with AR has recently been reported (Powe et al., 2010).  
The activation of mast cells and eosinophils and IgE production were induced after nasal 
stimulation with aeroallergens in reported study. Patients had an immediate or dual 
response to NAPTs (nasal allergen provocation test) accompanied by release of tryptase, 
ECP (eosinophil cationic protein) and sIgE in nasal secretions. The kinetics study of 
tryptase showed a strong correlation with nasal itching and sneezing and a pattern of 
release that varied with the type of response.  
This rapid secretion of sIgE after challenge, with basal detection of sIgE in some 
patients, supports the existence of a persistent local production of sIgE in nasal mucosa 
that rapidly increases after allergen stimulation. These findings have led researchers in 
considering the need to evaluate whether local production of sIgE in patients with other 
apparently nonallergic respiratory diseases, such as chronic rhinosinusitis with or 
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without nasal polyps (van Zele et al., 2007; Sabirov et al., 2008), asthma (Humbert et 
al., 1996; Takhar et al., 2007; Campo et al., 2011)  or conjunctivitis, could exist. 
 
1.3.6 Diagnosis of allergic rhinitis 
 There are several tests done in the medical line to diagnose AR. It includes 
physical examination (history of medical problems and family history of allergies). The 
demonstration of skin testing and allergen-specific IgE are used to confirm the diagnosis 
of AR as well as the guidance due to treatment process (Rijn et al., 1998). The previous 
study demonstrated that total IgE has poor clinical correlation and low predictive value 
than antigen-specific IgE antibodies in diagnosing of inhalant allergy (ARIA, 2001; 
Nguyen and Close, 2005). Specific IgE measurement (specific IgE serum immunoassay) 
or skin prick test is known to be useful (Ahlstedt and Murray, 2006). 
The important markers of the possible allergic causes of disorders of the upper 
respiratory tract are skin prick test and measurement of specific IgE (Droste et al., 
1996). However, skin testing is the standard method in diagnosing of AR (Chapnik and 
Hakemi, 2003). Skin prick test is used to identify specific allergen and to determine the 
sensitivity of the patients towards the allergen.  
Nasal cytology is also one of the methods to diagnose AR. Nasal secretions are stained 
with hematoxylin and eosin. Generally, the presence of eosinophils and goblet cells is 
suggestive of allergy while the presence of neutrophils and bacteria is referred to 
infection.     
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1.3.7 Treatment of allergic rhinitis 
 The management of AR involves allergen avoidance, education, immunotherapy 
and pharmacologic treatment (Corren, 2000; ARIA Pocket Guide, 2001; Rutkowski, 
2005; Lehman and Lieberman, 2007; Bousquet et al., 2008). Patients should report the 
response of medications like corticosteroids and antihistamine (Rondon et al., 2007; 
2008).  
The allergen avoidance is an effective treatment strategy (Lehman and Lieberman, 
2007). However, an avoidance of known allergic triggers always non-practical 
(Dykewicz, 1998; Rosenwasser, 2002; ARIA, 2004; Plaut and Valentine, 2005). An 
improvement to a level of regular medications in some patients might be resulted from 
decreased exposure to indoor allergens (Bousquet et al., 2001).  
The allergic management is important in order to control allergic symptoms and 
maintain the healthy lifestyle. These interventions can control the symptoms with 
minimal side effects in most patients. The medications such as anti-IgE therapy and 
cytokine antagonist may provide some alternative relief to patients (Corren, 2000).  
Antihistamines can control the symptoms of itching, sneezing, rhinorrhoea and eye 
irritation but not nasal congestion (Spector, 1997; Rutkowski, 2005). Intranasal steroids 
are used for patients with more severe symptoms (Rosenwasser, 2002). 
Montelukast, which is one leukotriene antagonist has been approved for the seasonal AR 
treatment. Those not controlled with antihistamine and nasal corticosteroids had an 
option to use it. It works on the same pathway of corticosteroids. It is helpful to relieve 
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the symptoms for those with mild allergies and mild asthma (Rutkowski, 2005). A mast 
cell stabilizer, cromolyn sodium prevents the mast cells from releasing chemical 
mediators thus preventing the allergic response. It reduces nasal itching, sneezing, runny 
nose and nasal congestion (Spector, 1997; Rutkowski, 2005).  
Specific immunotherapy, anti-IgE therapy also helps in treating AR and other allergic 
diseases. The reduction of IgE included systemic administration of humanized 
monoclonal anti-IgE antibodies (Corren, 2000; Abbas & Lichtman, 2003). A 
recombinant humanized monoclonal anti-IgE antibody, omalizumab can blocks the 
interaction of IgE with its receptors (Owen, 2007). 
Cytokine-based therapies may lead in AR treatment due to recognition that allergy is 
associated with imbalanced TH1/TH2 activity. Cytokines themselves or pharmacological 
agents can be the treatment agents that can modulate specific cytokines profiles. 
Recombinant cytokines are being studied currently in a variety of allergic diseases. 
However, high pharmacological doses of recombinant cytokines may create other 
imbalances in the host that may lead to other disease problems (Hannigan and Pallister, 
2000).        
 
1.4 Atopic asthma 
 Asthma is one of the common diseases of childhood and causing substantial 
morbidity (Asher et al., 1995; The International Study of Asthma and Allergies in 
Childhood (ISAAC) Steering Committee, 1998). Atopic asthma (AA) is also linked with 
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the immune system just like the other allergic reactions (Barnes, 2000). AA is a chronic 
disease that affects approximately 4.0% to 5.0% of the members in the certain country 
(McFadden and Gilbert, 1992). This disease is characterized by reversible airway 
obstruction, chronic inflammation of bronchial mucosa and bronchial 
hyperresponsiveness. Identification of AA has the potential to improve the knowledge 
and functional status, thus can cut down the cost and expenditure on health care 
(Nicklas, 1997; Kuda, 1998; Serra-Batles et al., 1998). 
 
1.4.1 Prevalence study of atopic asthma 
 The previous study reported the increasing prevalence of AA due to the 
improvement of the treatment, diagnosis and understanding of the disease itself 
(Strachan et al., 1997; Beasley et al., 1998; Linneberg et al., 2000; Ulrik et al., 2000). 
Asthma, has become increasingly common in industrialized nations. It affects about 
15.0% of children and 10.0% of adults in the affluent countries. The previous study 
recorded, a smaller proportion of AA was recorded as death in children (Panickar et al., 
2005). 
An estimated 300 million people are affected by asthma as recorded in worldwide 
(Beasley, 2004; Masoli et al., 2004). The prevalence of asthma ranges around 1.0%-
18.0% of the population in different countries regarding to the application of 
standardized methods in measuring of the prevalence of asthma in children and adults 
(Beasley, 2004; Urrutia et al., 2007). Its prevalence has increased in some countries 
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(Carvajal-Uruena et al., 2005; Yan et al., 2005). However, it has stabilized and begun to 
decline in other countries (Garcia-Marcos et al., 2004; Asher et al., 2006).  
World Health Organization (WHO), has estimated that asthma has affected 15 million 
disability-adjusted life-years annually lost which representing 1.0% of total global 
disease burden (Pachter et al., 2002). The cost of controlling asthma is high. However, 
the cost of not treating asthma correctly is even higher (Accordini et al., 2006; Briggs et 
al., 2006; Sullivan et al., 2007).  
The prevalence of asthma in Malaysia was likely to increase. Previous study done in 
Malaysia reported 45.0% out of 404 patients enrolled in the study showed daytime 
asthma symptoms, 42.0% reported sleep disturbances due to asthma and 40.0% recorded 
getting asthma during exercises (Lai et al., 2003). AA has significant impact on quality 
of life.    
   
1.4.2 Aetiology of atopic asthma  
 The aetiology of asthma is multifactorial. Genetic factors may control individual 
predispositions to asthma. Variation in the beta-adrenergic receptor gene of the 
(arginine) Arg-Arg type has been associated with adverse responses to inhaled, short-
acting beta-agonist inhalers (Barnes, 2000).  
Asthma attacks have been linked to exercise and respiratory infections. The exposure to 
environmental factors such as allergens, tobacco smoke, indoor and outdoor air 
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pollution are the reasons of asthmatic attacks. However, it can be reduced by avoiding 
the exposure to known triggers and taking medications (Barnes, 2000).  
There are associations between air pollution exposures and asthma in the previous 
reported studies. The researchers have found an association between increased hospital 
admissions for asthma with particulate matter and outdoor air pollutant. The phenotype 
of the familial aggregation associated with AA has been described in the several studies 
(Davis and Bulpitt, 1981; Jenkins et al., 1993; Abdullrazzaq et al., 1994).  
  
1.4.3 Clinical manifestations of atopic asthma 
 The clinical manifestations of asthma includes recurrent wheezing, difficulty in 
breathing, chest tightness, sleep disturbances, limitations of daily activity, impairment of 
lung function and rescue medications usage (Bateman et al., 2008). The other symptoms 
of asthma are nasal congestion, runny nose and eye irritation. The wheezing sound 
usually accompanies exhalation. Asthma can also occur without wheezing (Global 
Initiative for Asthma, 2006).  
Symptoms may be triggered by exercise. Some asthma attacks are triggered by cold, 
heat or stress. This often causes worsening of symptoms. The symptoms occur or 
worsen at night and awakening the patient. Reversibility airflow obstruction is 
determined by an increase in FEV1 of >200 mL and ≥12% from baseline measure after 
inhalation of short-acting β2-agonist (SABA).  
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1.4.4 Scoring system of atopic asthma (GINA classification) 
 Global Initiative for Asthma (GINA) was implemented to develop a network of 
individuals, organizations and public health officials for the dissemination of 
information regarding the care of patients with asthma, while at the same time assuring a 
mechanism to incorporate the results of scientific investigations into asthma care 
(Global Initiative for  Asthma, 2002). The classifications of AA are listed in Table 1.2. 
 
Table 1.2 : Classification of atopic asthma by using GINA classification 
 
Characteristic 
 
Controlled 
(All of the 
following) 
 
Partly controlled 
(Any measure 
present in any 
week) 
 
Uncontrolled 
 
Daytime symptoms 
 
None (twice or 
less/week) 
 
More than twice / 
week 
 
 
 
 
Three or more 
features of 
partly 
controlled 
asthma present 
in any week 
 
Limitations of 
activities 
 
None 
 
Any 
 
Nocturnal symptoms 
/ awakening 
 
None 
 
Any 
 
Need for reliever / 
rescue treatment 
 
None (twice or 
less/week) 
 
More than twice / 
week 
 
 
Lung function (PEF 
or FEV1)++ 
 
Normal 
 
<80% predicted 
or personal best 
(if known) 
 
Exacerbation 
 
 
None 
 
One or more/year 
 
One in any 
week 
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